>>13397673>Antibody Therapy has efficacy at ANY stage of Infection, and it most certainly would have saved lives here.That hasn't been the case with monoclonal antibodies or convalescent plasma. Early treatment is beneficial, but treatment late in the infection has little impact on the outcome and increases the risk of the virus adapting to the antibodies. This adaption has been studied in patients. Misuse runs the risk of making the therapies ineffective for everyone.
>2. unknown effectiveness durationIt's certainly longer than antibody therapy, which has a very short half life. Unless you can arrange for infusions every couple of weeks, they're not a viable preventative measure and should be restricted to treating acute cases early in the infection.
>4. The S309 Antibody does not appear to be subject to #3 (which is KEY)Do you have evidence of this? The article you provided was against the original version of SARS-CoV-2. I'm not finding anything showing evidence it's effective against the variants. Considering we know that vaccine derived antibodies, monoclonal antibodies, and infection derived antibodies from early in the pandemic all have reduced binding capacity against recent variants, I don't know how you could believe S309 wouldn't also have reduced efficacy.
